Literature DB >> 8902389

Human papillomavirus vaccines for cervical cancer.

R W Tindle1.   

Abstract

The association of carcinoma of the uterine cervix with human papillomavirus indicates that vaccine strategies which target the virus could be useful in the control of disease progression. Recent advances have centered on directing the immune response to prevention of infection, to virus-infected (but nontransformed) cells and to virally transformed cells, with favourable results.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8902389     DOI： 10.1016/s0952-7915(96)80080-x

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  13 in total

1.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

Authors:  E Jäger; S Gnjatic; Y Nagata; E Stockert; D Jäger; J Karbach; A Neumann; J Rieckenberg; Y T Chen; G Ritter; E Hoffman; M Arand; L J Old; A Knuth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

2.  Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.

Authors:  Valérie Dutoit; Robert N Taub; Kyriakos P Papadopoulos; Susan Talbot; Mary-Louise Keohan; Michelle Brehm; Sacha Gnjatic; Paul E Harris; Brygida Bisikirska; Philippe Guillaume; Jean-Charles Cerottini; Charles S Hesdorffer; Lloyd J Old; Danila Valmori
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 3.  Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.

Authors:  Thinle Chodon; Amit A Lugade; Sebastiano Battaglia; Kunle Odunsi
Journal:  Hematol Oncol Clin North Am       Date:  2018-10-01       Impact factor: 3.722

4.  Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.

Authors:  A Lamikanra; Z K Pan; S N Isaacs; T C Wu; Y Paterson
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles.

Authors:  T Doan; K Herd; M Street; G Bryson; G Fernando; P Lambert; R Tindle
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

6.  Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

Authors:  E Jäger; Y Nagata; S Gnjatic; H Wada; E Stockert; J Karbach; P R Dunbar; S Y Lee; A Jungbluth; D Jäger; M Arand; G Ritter; V Cerundolo; B Dupont; Y T Chen; L J Old; A Knuth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

7.  Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors.

Authors:  Laurence M Wood; Patrick D Guirnalda; Matthew M Seavey; Yvonne Paterson
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

8.  Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.

Authors:  Michael D Street; Tracy Doan; Karen A Herd; Robert W Tindle
Journal:  Immunology       Date:  2002-08       Impact factor: 7.397

Review 9.  Rational approaches to immune regulation.

Authors:  Yvonne Paterson
Journal:  Immunol Res       Date:  2003       Impact factor: 4.505

Review 10.  Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions.

Authors:  Sarah Lynam; Amit A Lugade; Kunle Odunsi
Journal:  Clin Obstet Gynecol       Date:  2020-03       Impact factor: 1.966
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.